We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Edan Instruments

EDAN Instruments manufactures and distributes diagnostic medical equipments in the areas of obstetrics & gynecology, ... read more Featured Products: More products

Download Mobile App





Edan Debuts Next-Gen Blood Gas & Chemistry Analyzer and Patient Monitor at MEDICA 2021

By LabMedica International staff writers
Posted on 17 Nov 2021
Print article
Image: EDAN at MEDICA 2021 (Photo courtesy of EDAN Instruments, Inc.)
Image: EDAN at MEDICA 2021 (Photo courtesy of EDAN Instruments, Inc.)

EDAN Instruments, Inc. (Shenzhen, China) introduced five new products that are aimed at improving caregiver efficacy and resource accessibility at MEDICA 2021.

Three ready-to-launch products from EDAN, namely its next-gen blood gas and chemistry analysis system i20, 3rd Generation patient monitor iX Series, and the integrated portable version biofeedback and stimulation system PA4 Pro made their debut at MEDICA 2021. EDAN also highlighted its recently-introduced paperless tablet ECG machine iSE and 5-part auto hematology analyzer H60s.

EDAN’s iSE series 12/18 lead ECG machine features an outstanding tablet design and is intended to bring exceptional mobile experience and build a seamless connection to IT systems. It is suitable for applications such as ambulance or first-aid, as well as modern paperless informationized hospitals. Weighing less than one kg, it can start sampling automatically once all lead cables are connected and the desired signal quality is achieved. Its innovative self-adaptive AC filter technology ensures more desirable ECG signal quality in real clinical settings, especially under extreme environments with unstable voltage.

"The products we present this time is mind-changing," said EDAN's Senior Director of Global Marketing and Strategic Operations, Alex You. "In healthcare, efficacy speaks volumes about how technologies make a positive impact on paramedics' workflow, and further save time for patient interaction and more. On iSE, you can have a glance at our plan in IoMT. Intelligent healthcare and IoT-enabled devices have been our focus in recent years. We believe med-tech can improve patient care, and IoT can make this one step further."

"EDAN remains committed to improving people's lives by providing value-driven, user-centered products. The needs are continually evolving. And that's our job to adapt to it and continually optimize our products for the market," added Hao Zhang, CEO of EDAN. "Our mission is to make caregivers' work easier so that they could do more for patients. And the product we present this time just speaks for it."

Related Links:
EDAN Instruments, Inc. 

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Rickettsia Conorii Assay
RICKETTSIA CONORII ELISA

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Researchers have found the first evidence of testing for the alpha-synuclein protein in blood samples via seed amplification assay (Photo courtesy of Shutterstock)

Blood Test to Detect Alpha-Synuclein Protein Could Revolutionize Parkinson's Disease Diagnostics

Currently, Parkinson's disease (PD) is identified through clinical diagnosis, typically at a later stage in the disease's progression. There is a pressing need for an objective and quantifiable biomarker... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.